Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $9M | $237M | $9.5B | $6.3B | $11.1B | — |
| Enterprise Value | $9M | $237M | $9.5B | $6.3B | $11.1B | — |
| P/E Ratio → | -0.37 | — | — | 1403.65 | 3322.58 | — |
| P/S Ratio | 1446.27 | 38181.40 | — | — | — | — |
| P/B Ratio | — | — | — | 320.03 | 38.42 | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 38242.81 | — | — | — | — |
| EV / EBITDA | — | — | — | — | 3324.37 | — |
| EV / EBIT | — | — | — | 1400.81 | 3324.61 | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -1.9% | -1.9% | — | — | — | — |
| Operating Margin | -312016.9% | -312016.9% | — | — | — | — |
| Net Profit Margin | -394725.1% | -394725.1% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | -139.0% | 2.9% | 2.3% | — |
| ROA | -3353.2% | -3353.2% | -124.6% | 2.8% | 2.2% | -8.7% |
| ROIC | — | — | -24.0% | -0.7% | -0.5% | — |
| ROCE | — | — | -34.2% | -0.8% | -0.7% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | 0.01 | 103.24 |
| Net Debt / Equity | — | — | — | 0.00 | -0.00 | — |
| Net Debt / EBITDA | — | — | — | — | -0.15 | 103.24 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -2.27 | -2.27 | -13.06 | 498.88 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.09 | 0.20 | 3.62 | 1.00 |
| Quick Ratio | 0.14 | 0.14 | 0.09 | 0.20 | 3.62 | 1.00 |
| Cash Ratio | 0.13 | 0.13 | 0.00 | — | 1.64 | — |
| Asset Turnover | — | 0.00 | — | — | — | — |
| Inventory Turnover | 0.02 | 0.02 | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 0.1% | 0.0% | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 4.5% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 4.5% | 0.0% | — |
| Shares Outstanding | — | $1M | $689913 | $479478 | $898437 | $682812 |
Imminent insolvency and dilution
According to recent market data, ASBP trades at a P/S ratio of 1446.27, a valuation multiple that appears disconnected from the firm's negligible revenue base and suggests investors are pricing in extreme optionality rather than any tangible commercial progress or established diagnostic market share.
The current valuation multiple is essentially meaningless in a traditional fundamental context, as it implies a growth expectation that the company's current pre-commercial status cannot support. Investors should monitor whether this premium is driven by speculative interest in the underlying IP or a fundamental misunderstanding of the company's inability to generate recurring diagnostic service fees.
Based on historical financial filings, ASBP has consistently reported negative ROIC and ROE figures, with ROIC reaching -9.7% in 2024Q1, confirming that the company is currently destroying rather than compounding invested capital as it struggles to transition from research to a viable commercial diagnostic platform.
The persistent decay in returns on capital reflects the high fixed-cost burden of laboratory operations relative to the lack of revenue generation. This trend suggests that the company's current business model is structurally incapable of producing positive economic returns without a radical shift toward high-volume, automated testing capabilities.
As reported in quarterly data, the company's inventory days have reached extreme levels, with DIO peaking at 18,145 days in 2025Q4, which indicates a profound inability to manage laboratory consumables efficiently or convert research-stage assets into any form of meaningful commercial output.
The erratic nature of the cash conversion cycle metrics suggests that the company's operational processes are not yet optimized for commercial scale. The lack of consistent turnover ratios warrants further investigation into whether the firm's laboratory infrastructure is being utilized for productive research or merely maintained as a cost center.
According to the most recent balance sheet, ASBP maintains a current ratio of 0.17, a figure that highlights the company's extreme vulnerability and suggests that its $1M cash position is insufficient to sustain operations without immediate and likely dilutive external financing or asset liquidation.
The rapid deterioration of the current ratio compared to historical levels indicates that the company is facing a severe liquidity crunch. This position leaves the firm with virtually no margin for error, making it highly susceptible to any regulatory or operational shocks that could further increase its cash burn rate.
As noted in institutional research, the P/E ratio is the most commonly misapplied metric for ASBP, as the company's negative net margins render earnings-based valuation entirely irrelevant and obscure the firm's true status as a cash-burning, pre-commercial entity requiring a burn-to-cash analysis instead.
Using P/E multiples for a company with negligible revenue and massive operating losses provides a false sense of comparability to established diagnostic peers. Analysts should instead focus on the cash runway and the binary outcomes of clinical validation data to assess the company's survival prospects.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ASBP stock.
Aspire Biopharma Holdings, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Aspire Biopharma Holdings, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Aspire Biopharma Holdings, Inc. has -1.9% gross margin and -312016.9% operating margin.